Casma Therapeutics

Casma Therapeutics

  • Founded: 2017
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: Undisclosed
  • Product link:
  • Funding: $46M C Nov 2022; $50M B Sep 2020; $58.5M A May 2018
  • Investors: Amgen Ventures, Astellas Venture Management, Eisai Co., Euclidean Capital, Mirae Asset, Ono Venture Investment, Eventide Asset Management, Schroders Capital, The Column Group, Third Rock Ventures

job board

Short description:

Autophagy-focused Treatments

Drug notes:

2 additional undisclosed programs RD oncology, inflammation

Long description:

Casma Therapeutics is harnessing the power of autophagy to bring cures to patients with serious diseases. The traditional pharma approach is to use drugs to inhibit the active site of a disease-causing protein. An alternative strategy is to instead destroy the protein entirely. Autophagy is a major cellular degradation pathway that recycles damaged components. Casma’s approach is to boost autophagy and degradation by developing drugs against unique molecular targets generated from their platform. Initially Casma is focusing on new treatments for patients with unmet clinical needs including rare genetic diseases and broader areas such as neurodegeneration, metabolic disorders, and muscle degeneration.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy